Urovant Sciences Ltd. (UROV): Price and Financial Metrics


Urovant Sciences Ltd. (UROV)

Today's Latest Price: $10.07 USD

0.01 (0.10%)

Updated Jul 7 4:00pm

Add UROV to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UROV Daily Price Range
UROV 52-Week Price Range

UROV Stock Price Chart Technical Analysis Charts


UROV Price/Volume Stats

Current price $10.07 52-week high $15.98
Prev. close $10.06 52-week low $6.55
Day low $9.99 Volume 24,750
Day high $10.29 Avg. volume 71,978
50-day MA $9.84 Dividend yield N/A
200-day MA $10.77 Market Cap 310.15M

Urovant Sciences Ltd. (UROV) Company Bio


Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. The company was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd.


UROV Latest News Stream


Event/TimeNews Detail
Loading, please wait...

UROV Latest Social Stream


Loading social stream, please wait...

View Full UROV Social Stream

Latest UROV News From Around the Web

Below are the latest news stories about Urovant Sciences Ltd that investors may wish to consider to help them evaluate UROV as an investment opportunity.

Urovant Sciences Ltd (UROV) on Q4 2019 Results - Earnings Call Transcript

Urovant Sciences Ltd (UROV) Q4 2019 Earnings Conference Call June 18, 2020, 16:30 ET Company Participants Ryan Kubota - Executive Director, IR James Robinson - Principal Executive Officer & Director Cornelia Haag-Molkenteller - Chief Medical Officer, USI Ajay Bansal - CFO & SVP, Business Development Conference Call Participants Eric Joseph...

SA Transcripts on Seeking Alpha | June 19, 2020

Urovant Sciences EPS misses by $0.56

Urovant Sciences (UROV): Q4 GAAP EPS of -$1.68 misses by $0.56.Cash balance of $51.4MPress Release...

Seeking Alpha | June 18, 2020

Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results

Yahoo | June 18, 2020

Urovant Sciences Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / June 18, 2020 / Urovant Sciences Ltd. (NASDAQ:UROV) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on June 18, 2020 at 4:30 ...

Yahoo | June 18, 2020

Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals

Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd.

Yahoo | June 18, 2020

Read More 'UROV' Stories Here

UROV Price Returns

1-mo -14.66%
3-mo 11.89%
6-mo -27.34%
1-year 14.69%
3-year N/A
5-year N/A
YTD -35.07%
2019 135.36%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8437 seconds.